Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Oschner - Vice President of Investor Relations and Corporate Communications Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer and Executive Vice President of Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Tim Lugo - William Blair Oren Livnat - H.C. Wainwright Operator Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
- 08/13/2024
|
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
- Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago.
- 08/13/2024
|
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
- CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.
- 08/09/2024
|
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
- CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the commencement of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zevra. Zevra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 08/08/2024
|
Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference
- CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at Canaccord Genuity's 44th Annual Growth Conference in Boston, MA, on Wednesday, August 14, 2024, at 10:30 a.m. ET. Members of the executive team will be available for one-on-one investor meetings with registered attendees throughout the conference.
- 08/07/2024
|
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
- Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/06/2024
|
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
- CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC).
- 08/02/2024
|
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
- CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m.
- 07/30/2024
|
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
- The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
- 07/10/2024
|
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
- Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 07/10/2024
|
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
- CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information.
- 06/18/2024
|
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
- KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog
- 06/03/2024
|
Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Nichol Ochsner - VP, Investor Relations & Corporate Communications Neil Mcfarlane - President, CEO & Director LaDuane Clifton - CFO, Treasurer, Secretary Josh Schafer - Chief Commercial Officer & EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Tim Lugo - William Blair & Company Jonathan Aschoff - ROTH MKM Louise Chen - Cantor Fitzgerald Oren Livnat - H.C. Wainwright & Co. Kyle Qian - Canaccord Genuity Operator Good morning, everyone.
- 05/08/2024
|
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
- Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.34 per share a year ago.
- 05/08/2024
|
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
- Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~ 75% of covered lives as of May 1, 2024
- 05/08/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
- NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/06/2024
|
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
- CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET, to review its corporate and financial results for the first quarter of 2024.
- 05/01/2024
|
Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
- CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024.
- 04/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
- NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/28/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
- NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/20/2024
|
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
- The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile
- 04/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
- NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/12/2024
|
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
- CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into a new credit facility provided by leading biotech investors. Led by Perceptive Advisors and Healthcare Royalty, the new credit facility provides up to $100M in committed capital in three tranches: an initial draw of $60M at closing, a second tranche of up to $20M available until October 5, 2025, and a third tranche of up to $20M which becomes available upon approval of arimoclomol, the Company's product candidate for the treatment of Niemann Pick disease Type C (NPC), in each case subject to certain terms and conditions. As part of this transaction, the Company has retired its combined existing debt of approximately $43.1M.
- 04/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
- NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/04/2024
|
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
- Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET CELEBRATION, Fla.
- 03/28/2024
|
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
- KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
- 03/26/2024
|
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference being held virtually on April 8-9, 2024. The Company's presentation will take place on Monday, April 8, 2024, at 3:45 p.m. ET. Additionally, members of Zevra's management team will be available for one-on-one investor meetings with registered attendees throughout the conference.
- 03/25/2024
|
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
- Zevra Therapeutics, Inc. (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/21/2024
|
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
- CELEBRATION, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Thursday, March 28, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the fourth quarter and full year 2023.
- 03/18/2024
|
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
- The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is September 21, 2024 CELEBRATION, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for arimoclomol, an investigational orally delivered, first-in-class treatment for Niemann-Pick disease type C (NPC).
- 03/04/2024
|
Zevra Therapeutics to Participate at Upcoming Investor Conferences
- CELEBRATION, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at upcoming investor conferences in March 2024. Additionally, management will be available for one-on-one meetings with registered attendees at each of the conferences.
- 02/28/2024
|
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
- Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/15/2024
|
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually on Tuesday, February 13, 2024, at 9:20 a.m. ET. Additionally, members of Zevra's management team will be available for one-on-one investor meetings with registered attendees during the conference from February 13-14, 2024.
- 02/06/2024
|
Zevra Therapeutics, Inc. (ZVRA) Q3 2023 Earnings Call Transcript
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Neil McFarlane - President and Chief Executive Officer Christal Mickle - Co-Founder and Chief Product Development Officer LaDuane Clifton - Chief Financial Officer, Secretary and Treasurer Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Jonathan Aschoff - ROTH MKM Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Operator Good morning, everyone.
- 11/11/2023
|
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
- CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET, to review its corporate and financial results for the third quarter of 2023.
- 10/31/2023
|
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
- Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs
- 10/05/2023
|
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
- CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023, at 3:00 p.m. ET. Members of Zevra's management team will be available for one-on-one investor meetings with registered attendees during the conference.
- 09/20/2023
|
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- CELEBRATION, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 8:30 a.m. ET. Members of Zevra's management team will be available for one-on-one investor meetings with registered attendees during the conference from September 11-13, 2023.
- 09/05/2023
|
Zevra's Rare Find: Unearthing Value In Niche Rare Diseases The Market Overlooks
- Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns with Zevra's potential commercial efforts with arimoclomol in targeting rare diseases. Acer's Phase 3 trial for vascular Ehlers-Danlos syndrome fills an unmet need in the market and adds to Zevra's late-stage pipeline.
- 09/05/2023
|
How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%
- The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 09/04/2023
|
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
- CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that it will host a conference call and live audio webcast on Monday, August 14, 2023, at 8:30 a.m. ET, to review its corporate and financial results for the second quarter of 2023.
- 08/02/2023
|
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
- CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced executive management will participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, Tuesday, June 20 through Thursday, June 22, 2023.
- 06/13/2023
|
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
- Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.06 per share a year ago.
- 05/15/2023
|
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
- CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company's Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra's management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023.
- 05/10/2023
|
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
- CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that it will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET, to review its corporate and financial results for the first quarter of 2023.
- 05/09/2023
|
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Richard Pascoe - CEO LaDuane Clifton - Chief Financial Officer Travis Mickle - President and Co-Founder Christal Mickle - Chief Product Development Officer and Co-Founder Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH MKM Partners Louise Chen - Cantor Fitzgerald Oren Livnat - H.C. Wainwright Operator Good day, and welcome to the Zevra Therapeutics Fourth Quarter and Full Year 2022 Update Call.
- 03/10/2023
|
Zevra Therapeutics to Present at 35th Annual Roth Conference
- CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that Richard W. Pascoe, the Company's Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT. In addition, Zevra management will be available for in-person or virtual one-on-one investor meetings during the conference from March 12-14.
- 03/06/2023
|
